Literature DB >> 18398596

[Bladder carcinoma cell lines as models of the pathobiology of bladder cancer. Review of the literature and establishment of a new progression series].

J Hatina1, W Huckenbeck, H Rieder, H-H Seifert, W A Schulz.   

Abstract

BACKGROUND: Tumour cell lines represent valuable preclinical models to decipher underlying biology and identify potential therapy targets and pharmacologically useful compounds. Approximately 50 human bladder cancer cell lines have been established to date, mainly from invasive and metastatic tumours. Two of these, namely T24 and 253J, were experimentally further developed into progression series. These models have provided important insights into later tumour progression events and metastatic dissemination. Only a few cell lines are available as models of non-invasive papillary bladder cancer and no progression series have yet been established.
MATERIAL AND METHODS: During the course of establishing a doxorubicin-resistant variant cell line of the human papillary bladder carcinoma cell line BFTC-905, a unique cell colony was identified, apparently involving cells with divergent growth patterns. Subsequent subculturing yielded three daughter cell lines, BFTC-905-compact, BFTC-905-diffuse und BFTC-905-diffuse M. Their fundamental characterization included basic cell morphology, cell membrane expression of E-Cadherin, karyotype analysis, invasion and colony forming capacity in soft agar. The clonal origin of the newly established daughter cell lines was assessed by means of molecular genetic methods.
RESULTS: We could identify important differences in multiple transformation related traits among the cell lines of the BFTC-905 progression series. Both diffuse cell lines (BFTC-905-diffuse und BFTC-905-diffuse M) differed from the BFTC-905-compact cell line by growing in a less organized,"diffuse" manner, which involved colonies of cells exhibiting apparently normal cell-to-cell adhesion as well as individual cells outside of them. This diminution of the cell-to-cell adhesion was accompanied by a corresponding decrease of membranous E-Cadherin. The BFTC-905-diffuse M cell line displayed a dramatic increase in the overall chromosome number, resulting in a hypertetraploid karyotype. At the same time, this cell line, as the only one in the progression series, acquired the ability to grow independent of anchorage in soft agar. All three cell lines remained noninvasive. Allelic distribution of highly polymorphic DNA-markers in the cell lines of the BFTC-905 progression series provided unequivocal evidence of their common origin.
CONCLUSION: The newly established BFTC-905 progression series manifests two aspects of the early progression of non-invasive bladder carcinoma, not exhibited by any other progression series published so far, namely dynamic changes in the expression of E-Cadherin and a complex karyotypic evolution. It may thus contribute important insights into further understanding of the pathobiology of bladder cancer.

Entities:  

Mesh:

Year:  2008        PMID: 18398596     DOI: 10.1007/s00120-008-1687-4

Source DB:  PubMed          Journal:  Urologe A        ISSN: 0340-2592            Impact factor:   0.639


  43 in total

1.  Superficial urothelial (umbrella) cells. A potential cause of abnormal DNA ploidy results in urine specimens.

Authors:  E M Wojcik; R J Brownlie; T J Bassler; M C Miller
Journal:  Anal Quant Cytol Histol       Date:  2000-10       Impact factor: 0.302

2.  Multi-target fluorescence in situ hybridization in bladder washings for prediction of recurrent bladder cancer.

Authors:  Tobias Zellweger; Gabriel Benz; Gieri Cathomas; Michael J Mihatsch; Tullio Sulser; Thomas C Gasser; Lukas Bubendorf
Journal:  Int J Cancer       Date:  2006-10-01       Impact factor: 7.396

3.  Influence of the microenvironment on invasiveness of human bladder carcinoma cell lines.

Authors:  E M Bindels; M Vermey; N J De Both; T H van der Kwast
Journal:  Virchows Arch       Date:  2001-10       Impact factor: 4.064

4.  Established cell line of urinary bladder carcinoma (T24) containing tumour-specific antigen.

Authors:  J Bubeník; M Baresová; V Viklický; J Jakoubková; H Sainerová; J Donner
Journal:  Int J Cancer       Date:  1973-05       Impact factor: 7.396

5.  High susceptibility of human c-Ha-ras proto-oncogene transgenic rats to carcinogenesis: a cancer-prone animal model.

Authors:  Hiroyuki Tsuda; Katsumi Fukamachi; Yutaka Ohshima; Shinobu Ueda; Yoichiro Matsuoka; Tetsuya Hamaguchi; Takamasa Ohnishi; Nobuo Takasuka; Akihiro Naito
Journal:  Cancer Sci       Date:  2005-06       Impact factor: 6.716

6.  RhoGDI2 is an invasion and metastasis suppressor gene in human cancer.

Authors:  John J Gildea; M Jabed Seraj; Gary Oxford; Michael A Harding; Garret M Hampton; Christopher A Moskaluk; Henry F Frierson; Mark R Conaway; Dan Theodorescu
Journal:  Cancer Res       Date:  2002-11-15       Impact factor: 12.701

Review 7.  Review of metastatic bladder cancer.

Authors:  L C Pagliaro; P Sharma
Journal:  Minerva Urol Nefrol       Date:  2006-03       Impact factor: 3.720

8.  Multivariate analysis of flow cytometric deoxyribonucleic acid parameters and histological features for prognosis of bladder cancer patients.

Authors:  M Tachibana; N Deguchi; S Baba; S Jitsukawa; M Hata; H Tazaki
Journal:  J Urol       Date:  1991-12       Impact factor: 7.450

9.  Isolation and characterization of metastatic variants from human transitional cell carcinoma passaged by orthotopic implantation in athymic nude mice.

Authors:  C P Dinney; R Fishbeck; R K Singh; B Eve; S Pathak; N Brown; B Xie; D Fan; C D Bucana; I J Fidler
Journal:  J Urol       Date:  1995-10       Impact factor: 7.450

10.  A new and reliable culture system for superficial low-grade urothelial carcinoma of the bladder.

Authors:  Hans-Helge Seifert; Andrea Meyer; Marcus V Cronauer; Jiri Hatina; Mirko Müller; Harald Rieder; Michele J Hoffmann; Rolf Ackermann; Wolfgang A Schulz
Journal:  World J Urol       Date:  2007-04-18       Impact factor: 3.661

View more
  6 in total

1.  Genomic characterization of three urinary bladder cancer cell lines: understanding genomic types of urinary bladder cancer.

Authors:  Rosário Pinto-Leite; Isabel Carreira; Joana Melo; Susana Isabel Ferreira; Ilda Ribeiro; Jaqueline Ferreira; Marco Filipe; Carina Bernardo; Regina Arantes-Rodrigues; Paula Oliveira; Lúcio Santos
Journal:  Tumour Biol       Date:  2014-01-24

2.  Functional analyses and prognostic significance of SFRP1 expression in bladder cancer.

Authors:  Anja Rogler; Emil Kendziorra; Johannes Giedl; Christine Stoehr; Helge Taubert; Peter J Goebell; Bernd Wullich; Michael Stöckle; Jan Lehmann; Sabrina Petsch; Arndt Hartmann; Robert Stoehr
Journal:  J Cancer Res Clin Oncol       Date:  2015-03-04       Impact factor: 4.553

3.  Establishment and characterization of human bladder cancer cell lines BexBra1, BexBra2, and BexBra4.

Authors:  Camila B Piantino; Juliana M Sousa-Canavez; Victor Srougi; Fernanda Salvadori; Raphael Kato; Pedro Paulo R Ayres; Miguel Srougi; Luiz Heraldo Camara-Lopes; Gilka Jorge Figaro Gattás; Cintia Fridman; Fernanda de Toledo; Isaque Santana; Kátia Ramos Moreira Leite
Journal:  In Vitro Cell Dev Biol Anim       Date:  2010-02       Impact factor: 2.416

4.  Role of two single nucleotide polymorphisms in secreted frizzled related protein 1 and bladder cancer risk.

Authors:  Anja Rogler; Sabine Hoja; Eileen Socher; Elke Nolte; Sven Wach; Wolf Wieland; Ferdinand Hofstädter; Peter J Goebell; Bernd Wullich; Arndt Hartmann; Robert Stoehr
Journal:  Int J Clin Exp Pathol       Date:  2013-09-15

5.  The UBC-40 Urothelial Bladder Cancer cell line index: a genomic resource for functional studies.

Authors:  Julie Earl; Daniel Rico; Enrique Carrillo-de-Santa-Pau; Benjamín Rodríguez-Santiago; Marinela Méndez-Pertuz; Herbert Auer; Gonzalo Gómez; Herbert Barton Grossman; David G Pisano; Wolfgang A Schulz; Luis A Pérez-Jurado; Alfredo Carrato; Dan Theodorescu; Stephen Chanock; Alfonso Valencia; Francisco X Real
Journal:  BMC Genomics       Date:  2015-05-22       Impact factor: 3.969

6.  Loss of MTUS1/ATIP expression is associated with adverse outcome in advanced bladder carcinomas: data from a retrospective study.

Authors:  Anja Rogler; Sabine Hoja; Johannes Giedl; Arif B Ekici; Sven Wach; Helge Taubert; Peter J Goebell; Bernd Wullich; Michael Stöckle; Jan Lehmann; Sabrina Petsch; Arndt Hartmann; Robert Stoehr
Journal:  BMC Cancer       Date:  2014-03-20       Impact factor: 4.430

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.